Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $878.64 million. The enterprise value is $1.09 billion.
| Market Cap | 878.64M |
| Enterprise Value | 1.09B |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 39.35 million shares outstanding. The number of shares has decreased by -5.52% in one year.
| Current Share Class | 39.35M |
| Shares Outstanding | 39.35M |
| Shares Change (YoY) | -5.52% |
| Shares Change (QoQ) | -4.82% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 105.69% |
| Float | 33.72M |
Valuation Ratios
The trailing PE ratio is 187.37 and the forward PE ratio is 7.24.
| PE Ratio | 187.37 |
| Forward PE | 7.24 |
| PS Ratio | 1.20 |
| Forward PS | 1.14 |
| PB Ratio | 1.34 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | 6.62 |
| P/OCF Ratio | 6.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.97, with an EV/FCF ratio of 8.20.
| EV / Earnings | 211.69 |
| EV / Sales | 1.48 |
| EV / EBITDA | 8.97 |
| EV / EBIT | 36.13 |
| EV / FCF | 8.20 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.63.
| Current Ratio | 4.73 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 3.02 |
| Debt / FCF | 3.10 |
| Interest Coverage | 1.82 |
Financial Efficiency
Return on equity (ROE) is 0.71% and return on invested capital (ROIC) is 1.35%.
| Return on Equity (ROE) | 0.71% |
| Return on Assets (ROA) | 1.35% |
| Return on Invested Capital (ROIC) | 1.35% |
| Return on Capital Employed (ROCE) | 2.74% |
| Weighted Average Cost of Capital (WACC) | 4.48% |
| Revenue Per Employee | $886,446 |
| Profits Per Employee | $6,198 |
| Employee Count | 829 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, PCRX has paid $8.03 million in taxes.
| Income Tax | 8.03M |
| Effective Tax Rate | 60.98% |
Stock Price Statistics
The stock price has decreased by -8.45% in the last 52 weeks. The beta is 0.29, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -8.45% |
| 50-Day Moving Average | 23.63 |
| 200-Day Moving Average | 23.50 |
| Relative Strength Index (RSI) | 40.54 |
| Average Volume (20 Days) | 449,160 |
Short Selling Information
The latest short interest is 6.60 million, so 16.76% of the outstanding shares have been sold short.
| Short Interest | 6.60M |
| Short Previous Month | 6.99M |
| Short % of Shares Out | 16.76% |
| Short % of Float | 19.56% |
| Short Ratio (days to cover) | 10.76 |
Income Statement
In the last 12 months, PCRX had revenue of $734.86 million and earned $5.14 million in profits. Earnings per share was $0.12.
| Revenue | 734.86M |
| Gross Profit | 583.01M |
| Operating Income | 30.10M |
| Pretax Income | 13.17M |
| Net Income | 5.14M |
| EBITDA | 121.29M |
| EBIT | 30.10M |
| Earnings Per Share (EPS) | $0.12 |
Balance Sheet
The company has $202.18 million in cash and $411.18 million in debt, with a net cash position of -$209.00 million or -$5.31 per share.
| Cash & Cash Equivalents | 202.18M |
| Total Debt | 411.18M |
| Net Cash | -209.00M |
| Net Cash Per Share | -$5.31 |
| Equity (Book Value) | 653.89M |
| Book Value Per Share | 16.63 |
| Working Capital | 406.17M |
Cash Flow
In the last 12 months, operating cash flow was $142.22 million and capital expenditures -$9.51 million, giving a free cash flow of $132.71 million.
| Operating Cash Flow | 142.22M |
| Capital Expenditures | -9.51M |
| Depreciation & Amortization | 91.19M |
| Net Borrowing | -218.99M |
| Free Cash Flow | 132.71M |
| FCF Per Share | $3.37 |
Margins
Gross margin is 79.34%, with operating and profit margins of 4.10% and 0.70%.
| Gross Margin | 79.34% |
| Operating Margin | 4.10% |
| Pretax Margin | 1.79% |
| Profit Margin | 0.70% |
| EBITDA Margin | 16.50% |
| EBIT Margin | 4.10% |
| FCF Margin | 18.06% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.52% |
| Shareholder Yield | 5.52% |
| Earnings Yield | 0.58% |
| FCF Yield | 15.10% |
Analyst Forecast
The average price target for PCRX is $29.67, which is 32.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.67 |
| Price Target Difference | 32.87% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 9.51% |
| EPS Growth Forecast (3Y) | 22.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 2.02 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.02 |
| Piotroski F-Score | 8 |